Clinical trial
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
NCT00158899 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00158899 |
|---|---|
| Title | GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol |
| Official title | A Multi-center, Three-staged With Interim Analyses, Parallel, Randomized, Double-blind, fenofibrate-and Placebo-controlled Proof of Concept and Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma High-density Lipoprotein Cholesterol (HDLc) and Triglycerides of Eight Weeks… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dyslipidaemias, Dyslipidaemia |
| Intervention type | Drug |
| Interventions | GW501516 oral tablets |
| Enrollment | 424 |
| Start date | Aug 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | May 30, 2017 |
| Countries | Belgium, Denmark, Estonia, Finland, France, Germany, Lithuania, Netherlands, Norway, Portugal, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: